TNF and thromboangiitis obliterans: Infliximab, a recombinant chimeric monoclonal antibody blocking the binding of TNF-α to its receptors, whose effectiveness has been demonstrated in three cases of severe steroid- and surgical-resistant TAO, achieved complete remission after interval administration [106–108].